This company has been acquired
Prometheus Biosciences (RXDX) Stock Overview
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RXDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Prometheus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$199.92 |
| 52 Week High | US$199.98 |
| 52 Week Low | US$25.65 |
| Beta | -0.49 |
| 1 Month Change | 3.51% |
| 3 Month Change | 77.52% |
| 1 Year Change | 684.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 690.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| RXDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 5.1% | 1.9% |
| 1Y | 684.3% | 40.0% | 20.3% |
Return vs Industry: RXDX exceeded the US Biotechs industry which returned 20.6% over the past year.
Return vs Market: RXDX exceeded the US Market which returned 17.7% over the past year.
Price Volatility
| RXDX volatility | |
|---|---|
| RXDX Average Weekly Movement | 20.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RXDX's share price has been volatile over the past 3 months.
Volatility Over Time: RXDX's weekly volatility has decreased from 26% to 20% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 97 | Mark McKenna | www.prometheusbiosciences.com |
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases.
Prometheus Biosciences, Inc. Fundamentals Summary
| RXDX fundamental statistics | |
|---|---|
| Market cap | US$9.56b |
| Earnings (TTM) | -US$150.56m |
| Revenue (TTM) | US$4.00m |
Is RXDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXDX income statement (TTM) | |
|---|---|
| Revenue | US$4.00m |
| Cost of Revenue | US$121.34m |
| Gross Profit | -US$117.34m |
| Other Expenses | US$33.22m |
| Earnings | -US$150.56m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.15 |
| Gross Margin | -2,937.17% |
| Net Profit Margin | -3,768.76% |
| Debt/Equity Ratio | 0% |
How did RXDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/17 21:24 |
| End of Day Share Price | 2023/06/15 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prometheus Biosciences, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hiroshi Shibutani | Goldman Sachs |
| Yatin Suneja | Guggenheim Securities, LLC |
| Christopher Howerton | Jefferies LLC |